Allogene Therapeutics Inc.

32.43+1.36+4.38%Vol 1.92M1Y Perf 21.53%
Jan 15th, 2021 16:00 DELAYED
BID31.88 ASK32.84
Open31.24 Previous Close31.07
Pre-Market- After-Market-
 - -%  - -
Target Price
46.91 
Analyst Rating
Moderate Buy 1.63
Potential %
44.65 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-86 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-100/-100/-20 
Growth Ranking
★★★     52.81
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-32 
Income Ranking
 —    -
Market Cap4.55B 
Earnings Rating
Buy
Price Range Ratio 52W %
39.93 
Earnings Date
25th Feb 2021

Today's Price Range

30.8133.64

52W Range

17.4355.00

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Week
16.36%
1 Month
19.71%
3 Months
-17.33%
6 Months
-21.87%
1 Year
21.53%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ALLO32.431.36004.38
AAPL127.14-1.7700-1.37
GOOG1 736.19-3.9900-0.23
MSFT212.65-0.3700-0.17
XOM47.89-2.4200-4.81
WFC32.04-2.7100-7.80
JNJ160.30-0.3500-0.22
FB251.365.72002.33
GE11.33-0.3300-2.83
JPM138.64-2.5300-1.79
Earnings HistoryEstimateReportedSurprise %
Q03 2020-0.55-0.525.45
Q02 2020-0.55-0.533.64
Q01 2020-0.57-0.5012.28
Q04 2019-0.69-0.5815.94
Q03 2019-0.54-0.507.41
Q02 2019-0.47-0.4112.77
Q01 2019-0.41-0.3221.95
Q04 2018-0.23-0.35-52.17
Earnings Per EndEstimateRevision %Trend
12/2020 QR-0.566.67Positive
12/2020 FY-2.131.39Positive
3/2021 QR-0.559.84Positive
12/2021 FY-2.392.85Positive
Next Report Date25th Feb 2021
Estimated EPS Next Report-0.56
Estimates Count10
EPS Growth Next 5 Years %1.00
Volume Overview
Volume1.92M
Shares Outstanding140.28M
Trades Count9.70K
Dollar Volume65.01M
Avg. Volume914.87K
Avg. Weekly Volume999.29K
Avg. Monthly Volume912.02K
Avg. Quarterly Volume884.83K

Allogene Therapeutics Inc. (NASDAQ: ALLO) stock closed at 32.39 per share at the end of the most recent trading day (a 4.38% change compared to the prior day closing price) with a volume of 1.93M shares and market capitalization of 4.55B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 190 people. Allogene Therapeutics Inc. CEO is David D. Chang.

The one-year performance of Allogene Therapeutics Inc. stock is 21.53%, while year-to-date (YTD) performance is 28.49%. ALLO stock has a five-year performance of %. Its 52-week range is between 17.43 and 55, which gives ALLO stock a 52-week price range ratio of 39.93%

Allogene Therapeutics Inc. currently has a PE ratio of -13.00, a price-to-book (PB) ratio of 3.49, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -25.31%, a ROC of -27.80% and a ROE of -27.92%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Allogene Therapeutics Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.56 for the next earnings report. Allogene Therapeutics Inc.’s next earnings report date is 25th Feb 2021.

The consensus rating of Wall Street analysts for Allogene Therapeutics Inc. is Moderate Buy (1.63), with a target price of $46.91, which is +44.65% compared to the current price. The earnings rating for Allogene Therapeutics Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Allogene Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Allogene Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 23.24, ATR14 : 3.24, CCI20 : 357.86, Chaikin Money Flow : 90.53, MACD : 0.22, Money Flow Index : 63.48, ROC : 21.58, RSI : 68.64, STOCH (14,3) : 85.78, STOCH RSI : 1.00, UO : 59.39, Williams %R : -14.22), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Allogene Therapeutics Inc. in the last 12-months were: Alison Moore (Option Excercise at a value of $313 812), Alison Moore (Sold 128 162 shares of value $5 163 562 ), Arie S. Belldegrun (Buy at a value of $6 879 954), David D. Chang (Sold 20 335 shares of value $392 615 ), Eric Schmidt (Sold 50 450 shares of value $1 737 591 ), Rafael Amado (Sold 16 538 shares of value $651 515 ), Veer Bhavnagri (Option Excercise at a value of $253 105), Veer Bhavnagri (Sold 66 553 shares of value $2 448 087 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
11 (68.75 %)
10 (62.50 %)
9 (60.00 %)
Moderate Buy
0 (0.00 %)
1 (6.25 %)
1 (6.67 %)
Hold
5 (31.25 %)
5 (31.25 %)
5 (33.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.63
Moderate Buy
1.69
Moderate Buy
1.73

Allogene Therapeutics Inc.

Allogene Therapeutics Inc is the United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.

CEO: David D. Chang

Teplephone: +1 650 457-2700

Address: 210 East Grand Avenue, South San Francisco 94080, CA, USA

Number of employees: 190

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

61%39%

Bearish Bullish

56%44%

News

Stocktwits